Risk-adjusted melanoma skin cancer incidence rates in Whites (United States)
Risk-adjusted melanoma skin cancer incidence rates in Whites (United States)
复制标题
DOI：
10.1097/cmr.0b013e328349420f
复制
发表时间：
2011-12-01
影响因子：
2.2
通讯作者：
Merrill, Ray Martell
中科院分区：
文献类型：
--
作者：
Merrill, Ray Martell
本研究的目的是获得一个更好的基于人群的黑色素瘤皮肤癌风险的衡量标准。以前已经提出了一种方法来估计癌症发病率的监测，流行病学和最终结果（SEER）计划收集的数据。与美国传统报告的发病率不同，该方法使用第一原发性癌症并根据基于人群的癌症患病率进行调整，以获得更好的癌症风险测量。这项研究涉及白色男性和女性的SEER数据。传统的黑色素瘤发病率高估了男性的风险，从30-39岁年龄组的3.3%增加到80岁及以上年龄组的11.3%。妇女风险估计过高的比例从30-39岁年龄组的3.3%到80岁及以上年龄组的8.9%不等。当同时考虑原位和恶性黑色素瘤时，风险的高估更为明显。常规发病率的上升趋势略大于风险调整后的发病率（RAIR）的趋势。2007年，根据传统癌症发病率，估计白色人口中的恶性黑色素瘤病例数为男性37 636例（包括原位病例64 125例），女性28 935例（包括原位病例49 361例）。根据RAIRS，美国男性估计病例数为34 652例[（7.9%）; 55 413例（13.6%），包括原位病例]，女性为27 178例[（6.1%）; 44 467例（9.9%），包括原位病例]。我们的结论是RAIR是黑色素瘤皮肤癌风险的更好衡量标准，应用于估计美国癌症患者的数量。黑色素瘤研究21：535-540（C）2011年威科健康|利平科特威廉姆斯&威尔金斯。
The objective of this study was to obtain a better population-based measure of risk for melanoma skin cancer. A method has been previously proposed for estimating cancer incidence rates for data collected from the Surveillance, Epidemiology, and End Results (SEER) program. Unlike conventionally reported incidence rates in the USA, this method uses the first primary cancer and adjusts for population-based cancer prevalence to obtain a better measure of cancer risk. The study involves SEER data for white men and women. Conventional melanoma incidence rates overestimate risk for men, increasingly so from 3.3% in the age group of 30-39 years to 11.3% in the age group of 80 years and older. Overestimation in risk for women ranged from 3.3% in the age group of 30-39 years to 8.9% in the age group of 80 years and older. Overestimation of risk was more pronounced when both in-situ and malignant melanomas were considered. Increasing trends in conventional rates were slightly greater than trends in risk-adjusted incidence rates (RAIRs). In 2007, the estimated number of cases with malignant melanoma among the white population based on conventional cancer incidence rates is 37 636 (64 125 including in-situ cases) for men and 28 935 (49 361 including in-situ cases) for women. The estimated number of cases in the USA based on RAIRS is 34 652 [(7.9%); 55 413 (13.6%) including in-situ cases] for male and 27 178 [(6.1%); 44 467 (9.9%) including in-situ cases] for women. We concluded that RAIRs are a better measure of melanoma skin cancer risk and should be used for estimating the number of cancer patients in the USA. Melanoma Res 21:535-540 (C) 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.